Regeneron (REGN) reported $3.68 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.6%. EPS of $12.89 for the same period compares to $11.56 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.34 billion, representing a surprise of +9.91%. The company delivered an EPS surprise of +60.52%, with the consensus EPS estimate being $8.03.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.15 billion versus the four-analyst average estimate of $1.03 billion. The reported number represents a year-over-year change of -25.2%.
- Revenues- Praluent (alirocumab)- US: $65.8 million compared to the $54.57 million average estimate based on four analysts. The reported number represents a change of +17.3% year over year.
- EYLEA Sales- United States: $754.3 million versus the three-analyst average estimate of $686.01 million.
- Revenues- Libtayo- ROW: $128.7 million versus $125.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.9% change.
- Revenues- Other Revenue: $183.9 million versus $125.38 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +76% change.
- Revenues- Net product sales: $1.63 billion compared to the $1.46 billion average estimate based on six analysts. The reported number represents a change of -15% year over year.
- Total Bayer collaboration revenue: $415 million versus $388.54 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
- Revenues- Collaboration: $1.86 billion versus the five-analyst average estimate of $1.73 billion. The reported number represents a year-over-year change of +22.1%.
- Total Sanofi collaboration revenue: $1.44 billion compared to the $1.36 billion average estimate based on five analysts. The reported number represents a change of +26% year over year.
- Revenues- Libtayo- Total: $376.5 million versus the four-analyst average estimate of $322.48 million. The reported number represents a year-over-year change of +26.6%.
- Revenues- Kevzara (sarilumab)- Total: $152.2 million versus the two-analyst average estimate of $116.19 million. The reported number represents a year-over-year change of +38.7%.
- Revenues- Eylea (Aflibercept)- Total: $2.13 billion compared to the $1.42 billion average estimate based on two analysts. The reported number represents a change of -13% year over year.
View all Key Company Metrics for Regeneron here>>>
Shares of Regeneron have returned -0.4% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
